Parkinson's disease, Parkinsonism Nervous System Diseases
Conditions
Interventions
Parkinson’s disease (PD) is a common neurodegenerative disease, present in 1-2% of individuals aged = 65 years. The most common genetic risk factor for PD is a heterozygous mutation in the GBA1 gene.
Sponsors
Vanqua Bio Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 40-80 2. All participants must understand and provide written informed consent prior to any study-specific procedures 3. Able to speak, read, and understand study procedures in Dutch sufficiently to allow completion of all study assessments 4. Confirmed clinical diagnosis of Parkinson’s disease by a neurologist within the last 5 years, based on presence of bradykinesia and either resting tremor and/or muscular rigidity in at least one limb 5. Willing to be contacted regarding potential participation in future interventional clinical trials
Exclusion criteria
Exclusion criteria: 1. History of a significant medical or psychiatric comorbidity that would preclude the subject’s participation in an interventional clinical trial 2. Known GBA-1 mutation for Parkinson’s disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sequence of the full GBA1 gene, classified as wildtype or mutated, with specifications of the mutation measured using next-generation sequencing at one timepoint | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
Netherlands
Contacts
Public ContactEva Thijssen
Outcome results
None listed